



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)

C12N 15/12 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2018/096494

(22) International Filing Date:

20 July 2018 (20.07.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: **EUCURE (BEIJING) BIOPHARMA CO., LTD** [CN/CN]; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN).(72) Inventors: **YANG, Yi**; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **DONG, Chunyan**; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **YANG, Fang**; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **LU, Chengyuan**; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **SHEN, Yuele**; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **NI, Jian**; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **GUO, Yanan**; Rm.708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **CHEN, Yunyun**; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN). **XIE, Jingshu**; Rm. 708, Building 3, No. 88 Kechuang 6 Ave., BDA, Beijing 101111 (CN).(74) Agent: **BEIJING LINKTEC IP LAW FIRM (SPECIAL GENERAL PARTNERSHIP)**; Room 1705, Baoyuan Buiding, No. 16 Qinghua East Road, Haidian District, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: ANTI-CD40 ANTIBODIES AND USES THEREOF




FIG. 1

(57) Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*